Cancer cells are dependent on functional autophagy both within their cytoplasm and systemically in the host to maintain growth. How systemic autophagy directly contributes to tumor growth remains unclear. In a study published in Nature, Poillet-Perez et al. (2018) show that host autophagy helps to maintain the levels of circulating arginine that feed tumor growth.
A key feature of many cancers is their ability to activate nutrient scavenging pathways that help to fuel the metabolic requirements of rapid, uncontrolled growth. Autophagy is a highly conserved intracellular clearance and recycling pathway that maintains metabolic homeostasis and survival of cells during periods of starvation and stress (Kaur and Debnath, 2015) . Accordingly, cancers as diverse as lung, breast, pancreas, melanoma, and colorectal carcinomas co-opt autophagy to maintain their metabolic, proliferative, and survival capacity, and they are highly vulnerable to autophagy suppression (Onorati et al., 2018) . In addition to the wellestablished cell-intrinsic role for autophagy in tumorigenesis, recent studies have suggested that elevated autophagy in the host can also aid tumor growth (Sousa et al., 2016; Katheder et al., 2017) . Strong evidence for this idea derives from acute, systemic suppression of the essential autophagy gene Atg7, which leads to dramatic regression of aggressive KRAS-driven lung cancer in mice (Karsli-Uzunbas et al., 2014) . How the combined action of tumor-cell-autonomous and host autophagy synergizes to fuel neoplastic growth-and the specific contributions of host autophagy to tumor cell metabolism-is a wide open question. The study by Poillet-Perez and colleagues sheds light on these questions by revealing a critical and mechanistically surprising role for autophagy in the host liver for sustaining the growth of transplanted cancer cells ( Figure 1) .
In their study, the authors selected a diverse panel of mouse cancer cell lines derived from melanoma, urothelial carcinoma, and non-small-cell lung cancer (NSCLC) models and measured their growth rate as allografts in syngeneic autophagycompetent (Atg7 +/+ ) or -deficient (Atg7 D/D ) host mice. Strikingly, several allografted cancer cell lines showed impaired growth in Atg7 D/D hosts compared to growth in Atg7 +/+ hosts, whereas a subset of the cell lines were resistant to systemic autophagy deletion and grew equally well in Atg7 +/+ and Atg7 D/D hosts. To uncover the underlying mechanism for dependence on host autophagy in the sensitive lines, the authors performed comparative metabolite profiling of serum from Atg7 +/+ and Atg7 D/D mice. The host blood supply is a major source of nutrients for the tumor, and several circulating metabolites were significantly altered in Atg7 D/D hosts, most prominently a significant drop in arginine concentration. Explaining their dependence on circulating arginine as a nutrient source, several of the cancer cell lines tested lacked expression of key arginine biosynthesis enzymes, including argininosuccinate lyase (ASS1) and ornithine transcarbamylase (OTC). Defective arginine synthesis is a common metabolic vulnerability in cancer known as arginine auxotrophy (Patil et al., 2016) , and it is mitigated by increased uptake of exogenous arginine. Hence, the reduced growth rate of cancer cells lacking ASS1 and OTC in Atg7 D/D hosts likely reflects a dependence on systemic autophagy for supplying arginine to tumor cells. Interestingly, cell lines that were able to grow despite loss of host autophagy also lacked expression of ASS1 and OTC, suggesting that these lines either harbor intrinsic resistance to autophagy deficiency that is independent of arginine auxotrophy or are able to activate compensatory pathways (discussed below).
To determine how circulating arginine is depleted in Atg7 D/D host mice, the authors next performed serum proteomics analysis and identified the arginine-degrading enzyme arginase 1 (ARG1) as significantly enriched in serum from Atg7 D/D hosts relative to Atg7 +/+ controls. ARG1 is a liver-specific enzyme that degrades arginine to ornithine. Thus increased circu-lating ARG1 suggests that host autophagy deletion leads to release of ARG1 by the liver into the circulation. The authors hypothesize that increased release of ARG1 from the liver is directly responsible for the observed drop in arginine levels in the context of systemic Atg7 loss. Consistent with this hypothesis, the authors found increased levels of ornithine in the circulation and in the tumor allografts growing in Atg7 D/D mice. Importantly, dietary arginine supplementation was able to partially rescue circulating arginine levels and tumor growth in Atg7 D/D hosts.
Several conditions, including liver damage and inflammation, are known to stimulate release of ARG1 from hepatocytes (Morris, 2012) . Consistently, the authors observed that Atg7 D/D hosts display fatty liver disease, a hallmark of liver dysfunction. Based on these observations, the authors tested whether liver-specific deletion of Atg7 would lead to ARG1 release, depletion of circulating arginine, and subsequent impairment of tumor growth in a similar manner to that observed following whole-body Atg7 deletion. Indeed, liver-specific deletion of Atg7 recapitulated the phenotypes of whole-body Atg7 D/D hosts, albeit to a lesser degree. Whole-body conditional deletion and liver-specific deletion of Atg5 displayed similar results to Atg7 deficiency, confirming dependency on autophagy for maintenance of serum arginine and for tumor growth. Taken together, these data indicate that host autophagy supports tumorigenesis by maintaining levels of circulating arginine.
Several intriguing questions arise from this study. First, what are the underlying adaptive mechanisms that explain why some cancer cell lines are resistant to host autophagy deficiency while others are sensitive to its loss? It is interesting to note that, in this study, the resistant and sensitive melanoma cell lines share similar genetics (Braf V600E , PTEN, and CDKN2A homozygous loss) (Poillet-Perez et al., 2018) and dependence on exogenous arginine in vitro. One possibility is that alternate scavenging pathways may be activated in resistant tumors that help to maintain intra-tumoral arginine levels despite, or in response to, decreased circulating arginine. For example, induction of macropinocytosis, the process of bulk uptake of extracellular protein that is subsequently degraded via the lysosome, may provide a source of arginine in these cells that sustains tumor growth in autophagydeficient hosts.
It is notable that liver-specific autophagy inactivation is not as potent in suppressing tumor growth as whole-body suppression. The authors propose that autophagy activation in neighboring stromal cells and other distant organs could release nutrients that help feed tumor cells, as has been reported previously (Sousa et al., 2016; Katheder et al., 2017) . Whether, as shown in Drosophila (Katheder et al., 2017) , mammalian tumors actively trigger host autophagy at distant sites remains largely unknown. Serum proteomics analyses similar to those performed in the present study may aid in identifying circulating cytokines and signaling molecules that enable remote control of autophagy induction in distant tissues by tumor cells.
Finally, despite important roles for autophagy in modulation of immune cell function (Clarke and Simon, 2018) , the authors' data do not support a role for the immune system in suppression of tumor growth in autophagy-deficient 
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Growth of tumor allografts in autophagy-competent host mice is mediated in part through uptake of circulating arginine (red circle). Systemic or liverspecific loss of autophagy induces hepatocyte-mediated release of ARG1 and subsequent depletion of circulating arginine, leading to reduced growth of transplanted tumors.
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Cell Metabolism 29, February 5, 2019 237 hosts. Future studies analyzing tumors with greater mutational burdens and heightened immunogenicity may uncover an important role for immune cell subsets in regulation of tumor growth following systemic autophagy suppression.
In summary, this work points to an important role for host autophagy in facilitating the growth of a subset of melanoma, NSCLC, and urothelial tumors, and it highlights a key function for the liver in regulating the levels of circulating arginine ( Figure 1) . These results suggest that therapeutic amino acid depletion induced via either small molecules or recombinant enzymes may be an effective therapeutic strategy. Accordingly, phase I and II clinical trials utilizing pegylated derivatives of recombinant mammalian arginase or microbial arginine deiminase have displayed some clinical benefit and low toxicity in subsets of patients with ASS1negative tumors (Delage et al., 2010) . Together, these findings support further investigation into whether nutrient deprivation as a therapeutic strategy would be effective across diverse tumor settings.
Cancer cells must adapt to metabolic stress during tumor progression. In this issue of Cell Metabolism, Eichner et al. (2019) report that lung cancer development in genetically engineered mice requires the energy sensor AMP-activated protein kinase (AMPK). Their findings suggest that AMPK-mediated induction of lysosomal function supports cancer cell fitness, particularly during the early stages of tumorigenesis.
Neoplastic cells in evolving solid tumors are subject to changing metabolic stresses. Increased nutrient demand and oxidative stress due to cell growth or oncogenic signaling and limitations in nutrient availability can create barriers to tumorigenesis. In turn, adaptive processes must be engaged to restore metabolic homeostasis. A major, evolutionarily conserved sensor of nutrient states is the AMP-activated protein kinase (AMPK). In response to diverse cellular stresses, AMPK drives metabolic adaptation through balancing anabolic and catabolic pathways. Key outputs include suppression of protein and fatty acid synthesis, induction of fatty acid oxidation, promotion of glucose uptake, and nutrient scavenging via macroautophagy and macropinocytosis. Whether AMPK restrains tumorigenesis in vivo (e.g., by preventing aberrant activation of biosynthetic processes) or supports it (e.g., by enabling metabolic adaptation) has not been fully resolved. The LKB1 tumor suppressor (liver kinase B1; encoded by the STK11 gene) is one of two major
